vs
Guardant Health, Inc.（GH）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是VERACYTE, INC.的2.0倍（$281.3M vs $140.6M）。VERACYTE, INC.净利率更高（29.3% vs -45.7%，领先74.9%）。Guardant Health, Inc.同比增速更快（39.4% vs 18.5%）。VERACYTE, INC.自由现金流更多（$48.8M vs $-54.2M）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 20.5%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
GH vs VCYT — 直观对比
营收规模更大
GH
是对方的2.0倍
$140.6M
营收增速更快
GH
高出20.8%
18.5%
净利率更高
VCYT
高出74.9%
-45.7%
自由现金流更多
VCYT
多$103.0M
$-54.2M
两年增速更快
GH
近两年复合增速
20.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $140.6M |
| 净利润 | $-128.5M | $41.1M |
| 毛利率 | 64.6% | 72.5% |
| 营业利润率 | -43.0% | 26.4% |
| 净利率 | -45.7% | 29.3% |
| 营收同比 | 39.4% | 18.5% |
| 净利润同比 | -15.8% | 704.8% |
| 每股收益（稀释后） | $-1.01 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHVCYT
| Q4 25 | $281.3M | $140.6M | ||
| Q3 25 | $265.2M | $131.9M | ||
| Q2 25 | $232.1M | $130.2M | ||
| Q1 25 | $203.5M | $114.5M | ||
| Q4 24 | $201.8M | $118.6M | ||
| Q3 24 | $191.5M | $115.9M | ||
| Q2 24 | $177.2M | $114.4M | ||
| Q1 24 | $168.5M | $96.8M |
净利润GHVCYT
| Q4 25 | $-128.5M | $41.1M | ||
| Q3 25 | $-92.7M | $19.1M | ||
| Q2 25 | $-99.9M | $-980.0K | ||
| Q1 25 | $-95.2M | $7.0M | ||
| Q4 24 | $-111.0M | $5.1M | ||
| Q3 24 | $-107.8M | $15.2M | ||
| Q2 24 | $-102.6M | $5.7M | ||
| Q1 24 | $-115.0M | $-1.9M |
毛利率GHVCYT
| Q4 25 | 64.6% | 72.5% | ||
| Q3 25 | 64.7% | 69.2% | ||
| Q2 25 | 65.0% | 69.0% | ||
| Q1 25 | 63.3% | 69.5% | ||
| Q4 24 | 61.6% | 66.4% | ||
| Q3 24 | 61.1% | 68.2% | ||
| Q2 24 | 59.1% | 68.1% | ||
| Q1 24 | 61.2% | 64.5% |
营业利润率GHVCYT
| Q4 25 | -43.0% | 26.4% | ||
| Q3 25 | -37.3% | 17.4% | ||
| Q2 25 | -45.9% | -4.0% | ||
| Q1 25 | -54.6% | 2.5% | ||
| Q4 24 | -62.4% | 3.5% | ||
| Q3 24 | -61.3% | 10.4% | ||
| Q2 24 | -56.8% | 4.0% | ||
| Q1 24 | -59.2% | -4.8% |
净利率GHVCYT
| Q4 25 | -45.7% | 29.3% | ||
| Q3 25 | -35.0% | 14.5% | ||
| Q2 25 | -43.0% | -0.8% | ||
| Q1 25 | -46.8% | 6.2% | ||
| Q4 24 | -55.0% | 4.3% | ||
| Q3 24 | -56.3% | 13.1% | ||
| Q2 24 | -57.9% | 5.0% | ||
| Q1 24 | -68.2% | -1.9% |
每股收益（稀释后）GHVCYT
| Q4 25 | $-1.01 | $0.50 | ||
| Q3 25 | $-0.74 | $0.24 | ||
| Q2 25 | $-0.80 | $-0.01 | ||
| Q1 25 | $-0.77 | $0.09 | ||
| Q4 24 | $-0.90 | $0.07 | ||
| Q3 24 | $-0.88 | $0.19 | ||
| Q2 24 | $-0.84 | $0.07 | ||
| Q1 24 | $-0.94 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $362.6M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $1.3B |
| 总资产 | $2.0B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHVCYT
| Q4 25 | $378.2M | $362.6M | ||
| Q3 25 | $580.0M | $315.6M | ||
| Q2 25 | $629.1M | $219.5M | ||
| Q1 25 | $698.6M | $186.1M | ||
| Q4 24 | $525.5M | $239.1M | ||
| Q3 24 | $585.0M | $274.1M | ||
| Q2 24 | $933.7M | $235.9M | ||
| Q1 24 | $1.0B | $209.2M |
总债务GHVCYT
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHVCYT
| Q4 25 | $-99.3M | $1.3B | ||
| Q3 25 | $-354.5M | $1.3B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | $1.2B | ||
| Q3 24 | $-60.1M | $1.2B | ||
| Q2 24 | $-1.6M | $1.1B | ||
| Q1 24 | $68.3M | $1.1B |
总资产GHVCYT
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $48.8M |
| 自由现金流率自由现金流/营收 | -19.3% | 34.7% |
| 资本支出强度资本支出/营收 | 9.9% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $126.6M |
8季度趋势，按日历期对齐
经营现金流GHVCYT
| Q4 25 | $-26.4M | $52.6M | ||
| Q3 25 | $-35.4M | $44.8M | ||
| Q2 25 | $-60.3M | $33.6M | ||
| Q1 25 | $-62.7M | $5.4M | ||
| Q4 24 | $-64.5M | $24.5M | ||
| Q3 24 | $-51.1M | $30.0M | ||
| Q2 24 | $-94.0M | $29.6M | ||
| Q1 24 | $-30.3M | $-9.0M |
自由现金流GHVCYT
| Q4 25 | $-54.2M | $48.8M | ||
| Q3 25 | $-45.8M | $42.0M | ||
| Q2 25 | $-65.9M | $32.3M | ||
| Q1 25 | $-67.1M | $3.5M | ||
| Q4 24 | $-83.4M | $20.4M | ||
| Q3 24 | $-55.3M | $27.7M | ||
| Q2 24 | $-99.1M | $26.8M | ||
| Q1 24 | $-37.2M | $-11.1M |
自由现金流率GHVCYT
| Q4 25 | -19.3% | 34.7% | ||
| Q3 25 | -17.3% | 31.8% | ||
| Q2 25 | -28.4% | 24.8% | ||
| Q1 25 | -33.0% | 3.1% | ||
| Q4 24 | -41.3% | 17.2% | ||
| Q3 24 | -28.9% | 23.9% | ||
| Q2 24 | -55.9% | 23.4% | ||
| Q1 24 | -22.1% | -11.5% |
资本支出强度GHVCYT
| Q4 25 | 9.9% | 2.7% | ||
| Q3 25 | 3.9% | 2.1% | ||
| Q2 25 | 2.4% | 1.0% | ||
| Q1 25 | 2.2% | 1.6% | ||
| Q4 24 | 9.4% | 3.5% | ||
| Q3 24 | 2.2% | 1.9% | ||
| Q2 24 | 2.9% | 2.4% | ||
| Q1 24 | 4.1% | 2.2% |
现金转化率GHVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
